Regeneron Pharmaceuticals Inc 2017 SR
The report highlights Regeneron's first consolidated responsibility effort, focusing on improving lives through scientific innovation, fostering a culture of integrity, and building a better future. In 2017, the company achieved FDA and European Commission approvals for two new medicines and invested over $2 billion in R&D. Environmental achievements include diverting 94% of waste from landfills and reducing greenhouse gas emissions per employee by 24% since 2013. The company also committed $100 million over ten years to the Science Talent Search and saw 56% employee participation in volunteer activities.
Company: Regeneron Pharmaceuticals Inc
Sector: Manufacturing
Country: United States
Year: 2017
Type: SR
Pages: 58
Back to company
Regeneron Pharmaceuticals Inc
Responsibility Report
The report highlights Regeneron's first consolidated responsibility effort, focusing on improving lives through scientific innovation, fostering a culture of integrity, and building a better future. In 2017, the company achieved FDA and European Commission approvals for two new medicines and invested over $2 billion in R&D. Environmental achievements include diverting 94% of waste from landfills and reducing greenhouse gas emissions per employee by 24% since 2013. The company also committed $100 million over ten years to the Science Talent Search and saw 56% employee participation in volunteer activities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees